MannKind’s revolutionary inhaled diabetes drug, Afrezza, will soon be on pharmacy shelves, but these three hurdles could stand in the way of MannKind’s stock heading higher.
MannKind’s revolutionary inhaled diabetes drug, Afrezza, will soon be on pharmacy shelves, but these three hurdles could stand in the way of MannKind’s stock heading higher.